MedPath

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Phase 3
Recruiting
Conditions
Obesity
Interventions
Drug: Placebo
Registration Number
NCT06859268
Lead Sponsor
Eli Lilly and Company
Brief Summary

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
586
Inclusion Criteria
  • Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight
Exclusion Criteria
  • Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening

  • Have a prior or planned surgical treatment for obesity

  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity

  • Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

  • Have had within the past 90 days before screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • hospitalization for unstable angina, or
    • hospitalization due to congestive heart failure
  • Have New York Heart Association Functional Classification Class IV congestive heart failure

  • Have a history of chronic or acute pancreatitis

  • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Retatrutide Dose 1RetatrutideParticipants will receive retatrutide dose 1 administered subcutaneously (SC) for 116 weeks
Retatrutide Dose 1 to PlaceboPlaceboParticipants will receive retatrutide dose 1 administered SC for 80 weeks, then placebo administered SC for an additional 36 weeks
Retatrutide Dose 1 to Retatrutide Dose 2RetatrutideParticipants will receive retatrutide dose 1 administered SC for 80 weeks, then retatrutide dose 2 administered SC for an additional 36 weeks
Retatrutide Dose 1 to PlaceboRetatrutideParticipants will receive retatrutide dose 1 administered SC for 80 weeks, then placebo administered SC for an additional 36 weeks
Primary Outcome Measures
NameTimeMethod
Percent Change from Baseline in Body WeightWeek 0, Week 116
Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Waist CircumferenceWeek 0, Week 116
Percentage of Body Weight Reduction Achieved at Week 80 that is Maintained at Week 116Week 0, Week 80, Week 116
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)Week 0, Week 116

Trial Locations

Locations (50)

Southern California Clinical Research

🇺🇸

Santa Ana, California, United States

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

CMR of Greater New Haven, LLC

🇺🇸

Hamden, Connecticut, United States

ALL Medical Research, LLC

🇺🇸

Cooper City, Florida, United States

Florida International Medical Research

🇺🇸

Coral Gables, Florida, United States

Renstar Medical Research

🇺🇸

Ocala, Florida, United States

Charter Research - Winter Park

🇺🇸

Orlando, Florida, United States

Metabolic Research Institute, Inc.

🇺🇸

West Palm Beach, Florida, United States

Kubost Clinical Research - Marietta

🇺🇸

Marietta, Georgia, United States

North Georgia Clinical Research

🇺🇸

Woodstock, Georgia, United States

Pacific Diabetes & Endocrine Center

🇺🇸

Honolulu, Hawaii, United States

Alliance for Multispecialty Research, LLC

🇺🇸

Knoxville, Tennessee, United States

Springfield Clinic Main Campus

🇺🇸

Springfield, Illinois, United States

L-MARC Research Center

🇺🇸

Louisville, Kentucky, United States

Pennington Biomedical Research Center

🇺🇸

Baton Rouge, Louisiana, United States

Care Access - Lake Charles (Bayou Pines)

🇺🇸

Lake Charles, Louisiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Vector Clinical Trials

🇺🇸

Las Vegas, Nevada, United States

Dent Neurosciences Research Center, Inc

🇺🇸

Amherst, New York, United States

Carteret Medical Group

🇺🇸

Morehead City, North Carolina, United States

Care Access - Raleigh

🇺🇸

Raleigh, North Carolina, United States

Tekton Research, LLC.

🇺🇸

Moore, Oklahoma, United States

Altoona Center For Clinical Research

🇺🇸

Duncansville, Pennsylvania, United States

Care Access - Rapid City

🇺🇸

Rapid City, South Dakota, United States

Care Access - Houston

🇺🇸

Houston, Texas, United States

Southern Endocrinology Associates

🇺🇸

Mesquite, Texas, United States

Sleep Therapy Research Center

🇺🇸

San Antonio, Texas, United States

National Clinical Research, Inc

🇺🇸

Richmond, Virginia, United States

Northwest Clinical Research Center

🇺🇸

Bellevue, Washington, United States

Central Washington Health Services Association d/b/a Confluence Health

🇺🇸

Wenatchee, Washington, United States

Aggarwal and Associates Limited

🇨🇦

Brampton, Ontario, Canada

Circulate Cardiac & Vascular Centre

🇨🇦

Burlington, Ontario, Canada

Med Trust Research

🇨🇦

Courtice, Ontario, Canada

Winterberry Research Inc.

🇨🇦

Hamilton, Ontario, Canada

Care Access - Thunder Bay - Barton Street

🇨🇦

Thunder Bay, Ontario, Canada

Maple Leaf Research

🇨🇦

Toronto, Ontario, Canada

Centre de Medecine Metabolique de Lanaudiere (CMML)

🇨🇦

Terrebonne, Quebec, Canada

C.I.C. Mauricie inc.

🇨🇦

Trois-Rivières, Quebec, Canada

Atlantic Medical

🇬🇧

Penzance, Cornwall, United Kingdom

Rame Group Practice

🇬🇧

Torpoint, Cornwall, United Kingdom

St Bartholomew's Medical Centre

🇬🇧

Oxford, England, United Kingdom

Oakenhurst Medical Practice

🇬🇧

Blackburn, Lancashire, United Kingdom

Layton Medical Centre

🇬🇧

Blackpool, Lancashire, United Kingdom

HMC Health Group - Meadows Centre for Health

🇬🇧

Hounslow, London, City Of, United Kingdom

Cheadle Community Hospital

🇬🇧

Cheadle, Staffordshire, United Kingdom

Bradford on Avon Health Centre

🇬🇧

Bradford on Avon, Wiltshire, United Kingdom

FutureMeds - Liverpool

🇬🇧

Bromborough, Wirral, United Kingdom

FutureMeds - Birmingham

🇬🇧

Birmingham, United Kingdom

The Adam Practice

🇬🇧

Poole, United Kingdom

Woodstock Bower Surgery

🇬🇧

Rotherham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath